![Assaf Harofeh MC](https://trials-media.s3.amazonaws.com/orgs/assaf-harofeh-mc.jpeg)
Hyperbaric Oxygen Therapy in Patients With Chronic Stable Ischemic Heart Disease: An Option for...
Ischemic Heart DiseaseHyperbaric oxygen therapy (HBOT) is proposed as a possible in vivo angiogenic stimulator for improving microvascular myocardial perfusion and anginal symptoms as assessed by myocardial perfusion imaging and angina questionnaire in patients with chronic stable ischemic heart disease, when no other means to relief symptoms and/or ischemia are available.
![Meril Life Sciences Pvt. Ltd.](https://trials-media.s3.amazonaws.com/orgs/meril-life-sciences-pvt-ltd.jpeg)
Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
Coronary Artery DiseaseMeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe, Brazil and South Africa. Primary outcome of study will be Proportion of population reporting Major Adverse Cardiac Events at 6 months from the day of index Procedure.
![Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele](https://trials-media.s3.amazonaws.com/orgs/azienda-ospedaliera-universitaria-policlinico-vittorio-emanuele.jpeg)
Stenting of Renal Artery Stenosis in Coronary Artery Disease Study
Renal Artery StenosisLeft Ventricular HypertrophyThe Stenting of Renal Artery Stenosis in Coronary Artery Disease (RASCAD) study is a randomized controlled trial designed to evaluate the effect of renal artery stenting+medical therapy versus medical therapy alone on left ventricular mass progression and cardiovascular morbidity and mortality in patients affected by coronary artery disease and renal artery stenosis.
![General Hospital of Chinese Armed Police Forces](https://trials-media.s3.amazonaws.com/orgs/general-hospital-of-chinese-armed-police-forces.jpeg)
Influence of Varenicline on the Antiplatelet Action of Clopidogrel
Coronary Artery DiseaseThe purpose of this study is to investigate the effects of steady-state varenicline on the antiplatelet action of clopidogrel in patients with coronary artery disease.
![St. Francis Hospital, New York](https://trials-media.s3.amazonaws.com/orgs/st-francis-hospital-new-york.jpeg)
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
Coronary Artery DiseasePlatelet Aggregation Inhibitors1 moreThe purpose of this study is to determine the level of inhibition of platelet activation of an approved thienopyridine(clopidogrel or prasugrel) and aspirin regimen in the setting of drug eluting coronary stent implantation. In subjects with high residual levels of platelet reactivity after receiving either a maintenance or loading dose of either clopidogrel or prasugrel, a cross over of thienopyridine treatment to the alternate medication will occur. The study tests the hypothesis that adequate platelet inhibition will occur in subjects who have high levels of platelet reactivity and are subsequently switched from clopidogrel to prasugrel(loading or maintenance dose) without increased episodes of bleeding or MACE events at discharge and 30 days post Percutaneous Coronary Intervention (PCI).
![Herning Hospital](https://trials-media.s3.amazonaws.com/orgs/herning-hospital.jpeg)
The Effect of Enhanced External Counter Pulsation on Left Ventricular Systolic and Diastolic Function...
Ischemic Heart DiseaseEnhanced external counter pulsation (EECP) is a procedure performed on patients with ischemic heart disease. The treatment improves physical capacity and relieves angina pectoris. It is suitable for patients with persistent angina pectoris despite and for patients not amendable for coronary revascularization. Some studies demonstrate a relationship between diastolic and systolic blood pressure ratio (d/s ratio) and the effect of EECP. The aim of the investigators study is to understand the effect of EECP on left ventricular systolic and diastolic function assessed by trans-thoracic echocardiography (TTE). Hypothesis: EECP improves left ventricular systolic and diastolic function. There is a relationship between d/s ratio and aortic arterial stiffness EECP improves left ventricular diastolic function Standard TTE would be performed prior the EECP procedure, which lasts 60 min., and repeated every 15 minutes. Moreover the investigators would measure pulse wave velocity, a measure of aortic arterial stiffness, in order to investigate the relationship between the d/s ratio and arterial stiffness. The patients would be recruited among former study patients who have undergone EECP before. 20 patients with the best acoustic conditions would be selected and invited to enroll into the study.
![Seoul National University Hospital](https://trials-media.s3.amazonaws.com/orgs/seoul-national-university-hospital.jpeg)
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS...
Coronary Heart DiseaseObjectives To compare the safety and long-term effectiveness of coronary stenting with the new platform Everolimus-Eluting coronary stenting system (EECSS, Promus Element) compared with the Zotarolimus-Eluting coronary stenting system (ZECSS, Endeavor Resolute) in patients with coronary heart disease (CHD) To determine the short-term efficacy and safety of triple anti-platelet therapy (TAT, Aspirin 100mg qd, Clopidogrel 75mg qd and Cilostazol 100mg bid) compared with double-dose clopidogrel dual anti-platelet therapy (DDAT, Aspirin 100mg qd and Clopidogrel 150mg qd) in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) Study design Prospective, open-label, 2-by-2 multifactorial, randomized, multicenter trial to test the following in CHD patients Non-inferiority of Promus Element stent compared with Endeavor Resolute stent in reducing target lesion failure (TLF) Non-inferiority of TAT compared with DDAT in reducing net clinical outcome Patients will be randomized in a 2-by-2 factorial manner according to the type of drug eluting stent (EECSS vs. ZECSS) and the type anti-platelet regimen (TAT vs. DDAT). Randomization will also be stratified per presence of DM. Patient enrollment 3750 patients enrolled at 50 centers in Republic of Korea Patient follow-up Clinical follow-up will occur at 1, 3, 12, 24, 36 months after the procedure. Angiographical follow-up will be recommended to all participants at 13 months after the procedure. Investigator or designee may conduct follow-up as telephone contacts or office visits. Primary endpoint Target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI) and ischemia-driven target lesion revascularization (TLR) up to 12 months for the stent arm Net clinical outcome, defined as a composite of cardiac death, nonfatal MI, CVA and major bleeding by PLATO criteria at 1 month for the anti-platelet arm
![Cordis Corporation](https://trials-media.s3.amazonaws.com/orgs/cordis-corporation.jpeg)
Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems
Coronary Artery DiseaseCoronary AtherosclerosisThe objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.
![John Barnard](https://trials-media.s3.amazonaws.com/orgs/john-barnard.jpeg)
Molecular Determinants of Coronaruy Artery Disease
Coronary Artery DiseaseArteriovenous Malformations1 moreThe purpose of this study is to discover genes that may cause Coronary Artery Disease (CAD) or Arteriovenous Malformation (AVM).
![Acusphere](https://trials-media.s3.amazonaws.com/orgs/acusphere.jpeg)
Prognostic Assessment of Contrast Echocardiography (PACE Study)
Coronary Artery DiseaseThis study will demonstrate whether patients with prognostically-significant myocardial abnormalities detected with AI-700 contrast ECHO have a rate of cardiac death or MI that is higher than that of patients with normal AI-700 contrast ECHO.